CompBrief BY VELARION

Companies Cartesian Therapeutics, Inc.

Cartesian Therapeutics CEO salary & total pay, FY2025: $4.3M

Cartesian Therapeutics (RNAC) CEO salary, fiscal 2025: Carsten Brunn was paid a salary of $674,000 and $4,329,868 in total compensation. Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Cartesian Therapeutics, Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.

Carsten Brunn's complete compensation dossier

A PDF and a CSV sent to your email: Carsten Brunn's pay in every fiscal year Cartesian Therapeutics, Inc. reported it, line by line, with Carsten Brunn's equity grants and Cartesian Therapeutics, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$4,329,868CEO Carsten Brunn · source
Say-on-pay support99.01%Latest vote · source
CEO vs. named peers38th pct.Of 19 peer CEOs

CEO pay, last three years

  • $6,111,883FY2023
  • $7,314,211FY2024
  • $4,329,868FY2025

CEO total pay was $4,329,868 in fiscal 2025, down from $7,314,211 in fiscal 2024.

FY2025: salary $674,000 · bonus $0 · stock awards $973,475 · option awards $2,314,320

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Cartesian Therapeutics, Inc. in fiscal 2025?
As disclosed, Carsten Brunn (President and Chief Executive Officer) was the highest-paid executive at Cartesian Therapeutics, Inc. in fiscal 2025, with total compensation of $4,329,868.
How does Cartesian Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Carsten Brunn's total compensation ranked at the 38th percentile of Cartesian Therapeutics, Inc.'s disclosed peer group.
How did shareholders vote on Cartesian Therapeutics, Inc.'s executive compensation?
As disclosed, 99.01% of shareholders supported Cartesian Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Cartesian Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Cartesian Therapeutics, Inc. reported total board compensation of $894,659 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Carsten Brunn$674,000$0$973,475$2,314,320$363,960$0$4,113$4,329,868
President and Chief Executive Officer
Metin Kurtoglu163,4940775,931984,44260,4270489,7402,474,034
Former Chief Technology Officer
Christopher Jewell390,6650375,046661,814144,2000443,9822,015,707
Former Chief Scientific Officer
Blaine Davis475,8600372,460884,122205,572011,9131,949,927
Chief Financial Officer
Milos Miljkovic439,0000321,670766,422118,530011,9131,657,535
Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Carsten Brunn$4,329,868$7,314,211$6,111,883↓ −2,984,343
Metin Kurtoglu2,474,0342,713,06471,243↓ −239,030
Christopher Jewell2,015,7071,687,754—↑ +327,953
Blaine Davis1,949,9273,971,4122,494,759↓ −2,021,485
Milos Miljkovic1,657,5351,349,018—↑ +308,517

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The company designs its executive compensation program to reward performance consistent with strategic and financial results, emphasizing variable pay over fixed pay to attract, retain, and motivate top talent. The program balances short-term and long-term incentives, with a significant portion of target total direct compensation delivered in equity awards to align executive interests with long-term stockholder value creation.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantCompensia
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

No plan-based awards are on file for this fiscal year.

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Blaine DavisOption25,91777,74919.66—
Blaine DavisRSU—60,600—436,926
Blaine DavisOption—64,60016.93—
Blaine DavisRSU—22,000—158,620
Carsten BrunnOption49,759149,27419.66—
Carsten BrunnRSU—116,352—838,898
Carsten BrunnOption—169,10016.93—
Carsten BrunnRSU—57,500—414,575
Christopher JewellOption8,31724,94819.66—
Christopher JewellRSU—19,455—140,271
Christopher JewellOption—47,40016.93—
Christopher JewellRSU—16,100—116,081
Christopher JewellOption67,432—3.23—
Metin KurtogluOption10,6903,5643.23—
Metin KurtogluOption—47,40016.93—
Metin KurtogluRSU—16,100—116,081
Metin KurtogluOption79,099—1.41—
Metin KurtogluOption14,254—3.23—
Metin KurtogluOption65,499—19.66—
Milos MiljkovicOption5,85917,57419.66—
Milos MiljkovicRSU—13,704—98,806
Milos MiljkovicOption—56,00016.93—
Milos MiljkovicRSU—19,000—136,990
Milos MiljkovicOption30,528—3.23—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Carrie S. CoxIndependent · Compensation · Departed during FY$82,880$44,018$103,635—$0$230,533
Patrick Zenner, M.B.AIndependent · Lead Independent Director · Audit · Compensation · Nominating and Corporate Governance (Chair)71,84844,018101,044—0216,910
Timothy C. Barabe, M.B.AIndependent · Audit (Chair) · Compensation · Nominating and Corporate Governance65,00044,018101,044—0210,062
Murat Kalayoglu, M.D., Ph.DIndependent · Departed during FY58,83644,018101,044—0203,898
Nishan de Silva, M.D., M.B.AIndependent · Audit · Compensation57,50044,018101,044—0202,562
Kemal Malik, M.B.B.SIndependent · Compensation (Chair) · Science and Technology56,30444,018101,044—0201,366
Michael Singer, M.D., Ph.DIndependent · Nominating and Corporate Governance · Science and Technology52,50044,018101,044—0197,562
Timothy A. Springer, Ph.DIndependent · Nominating and Corporate Governance · Science and Technology47,50044,018101,044—0192,562
Adrian Bot, M.D., Ph.DIndependent · Science and Technology (Chair)2,06548,082108,960—0159,107
Carsten Brunn, Ph.DEmployee director · Board Chair—————0

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—

Total cost of the board

ComponentFY2025
Cash retainers and fees$494,433
Equity awards (grant-date value)$400,226
All other compensation$0
Total cost of the board$894,659

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Cartesian Therapeutics as a peer

Companies that benchmark against RNAC

1 company names RNAC as a compensation peer

Each company listed discloses RNAC in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named RNAC in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

Peer reciprocity

The companies Cartesian Therapeutics, Inc. names as compensation peers that name it back in their own disclosed peer groups.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Vor Biopharma2025Jean-Paul Kress$344,615$0$64,013,465$251,425$65,027,569
2Cogent Biosciences2025Andrew Robbins724,55412,993,25013,447,680561,60027,762,684
3MeiraGTx Holdings2025Alexandria Forbes840,0005,823,500——8,330,006
4Corvus Pharmaceuticals2025Richard Miller36,56606,989,00007,031,566
5Viridian Therapeutics2025Stephen Mahoney700,0001,058,0984,381,713630,0006,776,249
6Allogene Therapeutics2025David Chang724,0002,409,5372,588,329400,0106,136,093
7AnaptysBio2025Daniel Faga706,0111,592,0013,345,653465,9686,133,943
8Replimune Group2026Sushil Patel700,0003,376,0031,448,325315,0005,845,982
9Rezolute2026Nevan Charles Elam655,0003,220,7201,358,97205,711,410
10Candel Therapeutics2025Paul Peter Tak743,59203,916,028396,6535,344,561
11Savara2025Matthew Pauls660,0003,870,0000297,0004,845,000
12Cartesian Therapeutics, Inc.2025Carsten Brunn674,000973,4752,314,320363,9604,329,868
13Regenxbio2025Curran Simpson665,510777,4482,350,302387,3274,200,712
14Annexon2025Douglas Love670,83302,522,260371,2503,579,202
15Rocket Pharmaceuticals2025Gaurav Shah671,076806,7511,613,377403,0483,510,241
16Cabaletta Bio2025Steven Nichtberger659,55001,266,978446,9822,401,555
17Lineage Cell Therapeutics2025Brian Culley691,8000882,970518,9002,111,170
18MacroGenics2025Eric Risser561,56852,0001,049,386251,9002,078,854
194D Molecular Therapeutics2025David Kirn667,2520822,750560,5972,051,343
20Alector2025Arnon Rosenthal678,100422,876558,216325,4881,995,018

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Cartesian Therapeutics, Inc.not disclosednot disclosednot disclosedCompensia
4D Molecular Therapeutics140%Options 100not disclosedRadford (part of the Rewards Solutions practice at Aon plc)
Alector80%not disclosednot disclosedPearl Meyer & Partners, LLC
Allogene Therapeuticsnot disclosedOption 55 · RSU 25 · PSU 20not disclosedCompensia
AnaptysBio110%not disclosedNoAlpine Rewards
Annexon100% of target%not disclosednot disclosedAlpine Rewards
Cabaletta Bionot disclosedOption 100not disclosedAon
Candel Therapeuticsnot disclosednot disclosednot disclosedAon Plc d/b/a Radford
Cogent Biosciences135%not disclosedNoCompensia
Corvus Pharmaceuticalsnot disclosedOption 100not disclosednot disclosed
Lineage Cell Therapeuticsnot disclosednot disclosednot disclosedAnderson
MacroGenics85%not disclosednot disclosedAlpine Rewards, LLC
MeiraGTx Holdingsnot disclosedRSU 100not disclosedTotal Compensation Solutions
Regenxbio97%Options 75 · RSU 25not disclosedWillis Towers Watson
Replimune Group92.5%not disclosedNoPearl Meyer
Rezolute50%not disclosednot disclosednot disclosed
Rocket Pharmaceuticalsnot disclosednot disclosednot disclosedSemler Brossy
Savara90%RSU 100not disclosedAon
Viridian Therapeutics150%Options 75 · RSU 25not disclosedCompensia
Vor Biopharmanot disclosednot disclosednot disclosedAlpine Rewards, LLC

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-1213,659,709136,2176,033,19999.01%Passed
20252025-06-1319,701,123157,1321,72699.21%Passed
20232023-06-1663,731,5915,090,9401,074,19692.6%Passed
20222022-06-1759,419,3063,352,5862,678,80394.66%Passed
20212021-06-18—————
20202020-06-19—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20262026-06-1299.01%a
20252025-06-1399.21%b
20232023-06-1692.6%c

a. Approved under the standard stated in the filing — “Proposal 2: Approval of Compensation of Named Executive Officers -- The affirmative vote of the holders of a majority in voting power of the votes cast. | Abstentions: Abstentions and broker non-votes will have no effect.”.

b. Approved under the standard stated in the filing — “Proposal 2: Approval of Compensation of Named Executive Officers -- The affirmative vote of the holders of a majority in voting power of the votes cast. | Abstentions: Abstentions and broker non-votes will have no effect.”.

c. Approved under the standard stated in the filing — “Proposal 2: Approval of Compensation of Named Executive Officers -- The affirmative vote of the holders of a majority in voting power of the votes cast. | Abstentions: Abstentions and broker non-votes will have no effect.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

No insider equity transactions reported since the proxy statement.

Sources (41 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Carsten Brunn. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · page 38. As printed: 4,329,868. View filing ↗
  • Section 01, Metin Kurtoglu. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 2,474,034. View filing ↗
  • Section 01, Christopher Jewell. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 2,015,707. View filing ↗
  • Section 01, Blaine Davis. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 1,949,927. View filing ↗
  • Section 01, Milos Miljkovic. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 1,657,535. View filing ↗
  • Section 08, Carrie S. Cox. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 230,533. View filing ↗
  • Section 08, Patrick Zenner, M.B.A. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 216,910. View filing ↗
  • Section 08, Timothy C. Barabe, M.B.A. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 210,062. View filing ↗
  • Section 08, Murat Kalayoglu, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 203,898. View filing ↗
  • Section 08, Nishan de Silva, M.D., M.B.A. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 202,562. View filing ↗
  • Section 08, Kemal Malik, M.B.B.S. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 201,366. View filing ↗
  • Section 08, Michael Singer, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 197,562. View filing ↗
  • Section 08, Timothy A. Springer, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 192,562. View filing ↗
  • Section 08, Adrian Bot, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 159,107. View filing ↗
  • Section 08, Carsten Brunn, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 06, 2026 vote. Form 8-K, filed 2026-06-17. Item 5.07 · say-on-pay result. As reported: 99.01% (votes for as printed: 13,659,709). View filing ↗
  • Section 06, 2025 vote. Form 8-K, filed 2025-06-16. Item 5.07 · say-on-pay result. As reported: 99.21% (votes for as printed: 19,701,123). View filing ↗
  • Section 06, 2023 vote. Form 8-K, filed 2023-06-16. Item 5.07 · say-on-pay result. As reported: 92.6% (votes for as printed: 63,731,591). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 09b board cost (computed). Computed. Cash 494,433 + equity 400,226 + all other 0 = 894,659, summed across the director compensation table rows.
  • Vor Biopharma, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Vor Biopharma's own proxy. As printed: 65,027,569. View filing ↗
  • Cogent Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Cogent Biosciences's own proxy. As printed: 27,762,684. View filing ↗
  • MeiraGTx Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in MeiraGTx Holdings's own proxy. As printed: 8,330,006. View filing ↗
  • Corvus Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Corvus Pharmaceuticals's own proxy. As printed: 7,031,566. View filing ↗
  • Viridian Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Viridian Therapeutics's own proxy. As printed: 6,776,249. View filing ↗
  • Allogene Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics's own proxy. As printed: 6,136,093. View filing ↗
  • AnaptysBio, Section 10b CEO total. DEF 14A, filed 2026-06-29. CEO total compensation as printed in AnaptysBio's own proxy. As printed: 6,133,943. View filing ↗
  • Replimune Group, Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Replimune Group's own proxy. As printed: 5,845,982. View filing ↗
  • Rezolute, Section 10b CEO total. DEF 14A, filed 2026-10-21. CEO total compensation as printed in Rezolute's own proxy. As printed: 5,711,410. View filing ↗
  • Candel Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Candel Therapeutics's own proxy. As printed: 5,344,561. View filing ↗
  • Savara, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Savara's own proxy. As printed: 4,845,000. View filing ↗
  • Cartesian Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cartesian Therapeutics, Inc.'s own proxy. As printed: 4,329,868. View filing ↗
  • Regenxbio, Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in Regenxbio's own proxy. As printed: 4,200,712. View filing ↗
  • Annexon, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Annexon's own proxy. As printed: 3,579,202. View filing ↗
  • Rocket Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Rocket Pharmaceuticals's own proxy. As printed: 3,510,241. View filing ↗
  • Cabaletta Bio, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cabaletta Bio's own proxy. As printed: 2,401,555. View filing ↗
  • Lineage Cell Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Lineage Cell Therapeutics's own proxy. As printed: 2,111,170. View filing ↗
  • MacroGenics, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in MacroGenics's own proxy. As printed: 2,078,854. View filing ↗
  • 4D Molecular Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in 4D Molecular Therapeutics's own proxy. As printed: 2,051,343. View filing ↗
  • Alector, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Alector's own proxy. As printed: 1,995,018. View filing ↗
  • Section 10a, Lineage Cell Therapeutics reciprocity. DEF 14A. Lineage Cell Therapeutics names Cartesian Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
Get the full report — $299